LAS VEGAS, Apr 7, 2004 (BUSINESS WIRE) -- Jim Holmes, CEO, Lifeline Biotechnologies (OTC: LBTT) today announced the U.S. introduction of the company's Mastascope(TM) at the recent annual conference of the American Society of Breast Surgeons. Holmes noted, "This conference, for its size and influence, was as rewarding as our successful introduction of the Mastascope(TM) in Europe, two weeks ago."

Jonathan Reeves, Lifeline's vice president, who managed the company's product booth at the conference noted, "The first U.S. sale has been completed, payment received and the Mastascope(TM) system shipped. We will be actively following up on the numerous high-quality sales leads we've received, many of whom have requested hospital demonstrations. This introduction is our national kickoff of our rollout program. We are in the process of training our distributors and provided them with the materials and support needed to place this product with the target users and increase sales."

Dr. William Reeves, Lifeline's president and founder, commented, "This was a great opportunity for professor Louis Keith, our medical director and me to interface with some of the country's leading breast cancer authorities. The Mastascope(TM) technology was very well received by all the physicians who attended our booth, many of whom commented, 'The technology has finally caught up with the concept.'" Reeves commented further, "The Mastascope(TM) introduction, as a new concept, in early breast cancer detection will act as a forerunner to the First Warning(TM) Breast Monitor. In addition, the introduction of the Mastascope(TM) provided an excellent opportunity for management to discuss the underlying medical concepts that will be new to breast cancer detection, with some of the country's leading academics, who help form as well as influence medical opinion."

Reeves went on to comment, "Because of professor Keith's long-standing reputation and influence as a teacher and medical educator, Lifeline's opportunities to interface with medical professionals exists, who would otherwise be inaccessible to our company. Dr. Keith has opened doors for us that will be very helpful in development of this product in the market and the utilization of the Mastascope(TM) by physicians."

Lifeline's Web site address: www.lbti.com

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In particular, when used in the preceding discussion, the words "believe," "expects," "projects," "forecasts," "intends," "will," "anticipated," "could," or "may," and similar conditional expressions are intended to identify forward-looking statements within the meaning of the act and subject to the safe harbor created by the act. Except for historical information, all of the statements contained in the foregoing are forward-looking statements that involve a number of risks and uncertainties.

SOURCE: Lifeline Biotechnologies

Lifeline Biotechnologies Inc.
Jim Holmes, 775-324-1933
jholmes@lbti.com
or
Stock Enterprises
Investor Relations
Jim Stock, 866-242-2405
stockenter@aol.com